Dr. Zorn discusses 3-year data on Aquablation

Both the LUTS/BPH and testicular cancer guidelines were updated based on the availability of new literature, as identified through an AUA Update Literature Review process.

The data were presented at the recent American Urological Association Annual Meeting.

Questions spanned urologic conditions such as benign prostatic hyperplasia, overactive bladder, erectile dysfunction, kidney stones, Peyronie disease, and recurrent urinary tract infections.

“Even though there [are] many therapies that one can do, it's not a sign of anything ominous for most men,” says Kevin T. McVary, MD, FACS.

In this installment, Kevin Zorn, MD, FRCSC, FACS, highlights his disease-specific practice, BPH Canada, which he designates as a “one-stop shop” for patients with benign prostatic hyperplasia.

Aquablation is a “minimally invasive procedure [that] is safe with long-term durability and a low-side effect profile,” said urologist Dennis Bentley, MD.